Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc R Theoret

Showing results (31-40 of 103) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell LymphomasMaryam Sarraf Yazdy, Yvette L Kasamon, Wenjuan Gu, et al.
Human Gene Therapy|October 24, 2009
Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cellsMarc R Theoret, Cyrille J Cohen, Azam V Nahvi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple MyelomaAndrea C Baines, Bindu Kanapuru, Jay Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2025
FDA approval summary: Lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1 based immunotherapyLianne Hu, Chaohong Fan, Peter Bross, et al.
The Oncologist|April 1, 2022
FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic TherapyRobert Q Le, Xin Wang, Hongfei Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2018
FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic LeukemiaMaura C O'Leary, Xiaobin Lu, Ying Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid LeukemiaDaniel A Pollyea, John Barrett, Courtney D DiNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2017
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing RegimenAmy Barone, Dow-Chung Chi, Marc R Theoret, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid TumorsLeigh Marcus, Lola A Fashoyin-Aje, Martha Donoghue, et al.
Current Oncology Reports|August 28, 2020
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer ImmunotherapySirisha L Mushti, Flora Mulkey, Shenghui Tang, et al.
Pageof 11

Showing results (31-40 of 103) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2024
FDA Approval Summary: Polatuzumab Vedotin in the First-Line Treatment of Select Large B-Cell LymphomasMaryam Sarraf Yazdy, Yvette L Kasamon, Wenjuan Gu, et al.
Human Gene Therapy|October 24, 2009
Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cellsMarc R Theoret, Cyrille J Cohen, Azam V Nahvi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2024
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple MyelomaAndrea C Baines, Bindu Kanapuru, Jay Zhao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 23, 2025
FDA approval summary: Lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1 based immunotherapyLianne Hu, Chaohong Fan, Peter Bross, et al.
The Oncologist|April 1, 2022
FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic TherapyRobert Q Le, Xin Wang, Hongfei Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2018
FDA Approval Summary: Tisagenlecleucel for Treatment of Patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic LeukemiaMaura C O'Leary, Xiaobin Lu, Ying Huang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2021
Project 2025: Proposals for the Continued Success of Drug Development in Acute Myeloid LeukemiaDaniel A Pollyea, John Barrett, Courtney D DiNardo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 5, 2017
FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing RegimenAmy Barone, Dow-Chung Chi, Marc R Theoret, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 4, 2021
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid TumorsLeigh Marcus, Lola A Fashoyin-Aje, Martha Donoghue, et al.
Current Oncology Reports|August 28, 2020
Immune Response Evaluation and Treatment with Immune Checkpoint Inhibitors Beyond Clinical Progression: Response Assessments for Cancer ImmunotherapySirisha L Mushti, Flora Mulkey, Shenghui Tang, et al.
Pageof 11